100 related articles for article (PubMed ID: 38503564)
1. Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α.
Chan ST; Patel PR; Ransom TR; Henrich CJ; McKee TC; Goey AK; Cook KM; Figg WD; McMahon JB; Schnermann MJ; Gustafson KR
J Am Chem Soc; 2015 Apr; 137(16):5569-75. PubMed ID: 25892103
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia.
Pandey S; Singh R; Habib N; Tripathi RM; Kushwaha R; Mahdi AA
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1121-1134. PubMed ID: 38679971
[TBL] [Abstract][Full Text] [Related]
3. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.
Kizaka-Kondoh S; Konse-Nagasawa H
Cancer Sci; 2009 Aug; 100(8):1366-73. PubMed ID: 19459851
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia signaling during intestinal ischemia and inflammation.
Grenz A; Clambey E; Eltzschig HK
Curr Opin Crit Care; 2012 Apr; 18(2):178-85. PubMed ID: 22322265
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Use of Exercising in Hypoxia: Promises and Limitations.
Millet GP; Debevec T; Brocherie F; Malatesta D; Girard O
Front Physiol; 2016; 7():224. PubMed ID: 27375500
[No Abstract] [Full Text] [Related]
6. [Research progress of hypoxia-inducible factor 1 inhibitors against tumors].
Niu F; Li Y; Lai FF; Chen XG
Yao Xue Xue Bao; 2014 Jun; 49(6):832-6. PubMed ID: 25212028
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
[TBL] [Abstract][Full Text] [Related]
8. Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells.
Ball AT; Mohammed S; Doigneaux C; Gardner RM; Easton JW; Turner S; Essex JW; Pairaudeau G; Tavassoli A
J Am Chem Soc; 2024 Apr; 146(13):8877-8886. PubMed ID: 38503564
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming the Transcriptional Response to Hypoxia with a Chromosomally Encoded Cyclic Peptide HIF-1 Inhibitor.
Mistry IN; Tavassoli A
ACS Synth Biol; 2017 Mar; 6(3):518-527. PubMed ID: 27978620
[TBL] [Abstract][Full Text] [Related]
10. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.
Miranda E; Nordgren IK; Male AL; Lawrence CE; Hoakwie F; Cuda F; Court W; Fox KR; Townsend PA; Packham GK; Eccles SA; Tavassoli A
J Am Chem Soc; 2013 Jul; 135(28):10418-25. PubMed ID: 23796364
[TBL] [Abstract][Full Text] [Related]
11. Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia.
Neelam S; Brooks MM; Cammarata PR
Mol Vis; 2013; 19():1-15. PubMed ID: 23335846
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
13. Identification of small molecule compounds that inhibit the HIF-1 signaling pathway.
Xia M; Bi K; Huang R; Cho MH; Sakamuru S; Miller SC; Li H; Sun Y; Printen J; Austin CP; Inglese J
Mol Cancer; 2009 Dec; 8():117. PubMed ID: 20003191
[TBL] [Abstract][Full Text] [Related]
14. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Tanada M; Tamiya M; Matsuo A; Chiyoda A; Takano K; Ito T; Irie M; Kotake T; Takeyama R; Kawada H; Hayashi R; Ishikawa S; Nomura K; Furuichi N; Morita Y; Kage M; Hashimoto S; Nii K; Sase H; Ohara K; Ohta A; Kuramoto S; Nishimura Y; Iikura H; Shiraishi T
J Am Chem Soc; 2023 Aug; 145(30):16610-16620. PubMed ID: 37463267
[TBL] [Abstract][Full Text] [Related]
15. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Johns DG; Campeau LC; Banka P; Bautmans A; Bueters T; Bianchi E; Branca D; Bulger PG; Crevecoeur I; Ding FX; Garbaccio RM; Guetschow ED; Guo Y; Ha SN; Johnston JM; Josien H; Kauh EA; Koeplinger KA; Kuethe JT; Lai E; Lanning CL; Lee AYH; Li L; Nair AG; O'Neill EA; Stoch SA; Thaisrivongs DA; Tucker TJ; Vachal P; van Dyck K; Vanhoutte FP; Volckaert B; Wolford DG; Xu A; Zhao T; Zhou D; Zhou S; Zhu X; Zokian HJ; Walji AM; Wood HB
Circulation; 2023 Jul; 148(2):144-158. PubMed ID: 37125593
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
